-Reuters
AstraZeneca’s Forxiga Wins European Approval For Chronic Kidney Disease
The European Union has approved AstraZeneca plc’s (NASDAQ:AZN) Forxiga (dapagliflozin) for chronic kidney disease (CKD) in adults with and without type-2…
Litecoin’s Lee Says Statement Went To Litecoin Twitter In Error
-Reuters
Related Posts
High Tide Q4 Sales $53.87M Beat $42.57M Estimate
High Tide (NASDAQ:HITI) reported quarterly sales of $53.87 million which beat the analyst consensus estimate of $42.57 million by 26.54 percent.
Wells Fargo Downgrades Audacy to Equal-Weight, Announces $3 Price Target
Wells Fargo analyst Steven Cahall downgrades Audacy (NYSE:AUD) from Overweight to Equal-Weight and announces $3 price target.
Benzinga’s Daily Brief On Trending Tickers For Feb. 11, 2022: Cassava Sciences, Cleveland Cliffs, GameStop, and More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
The data on the trending tickers is compiled from a list of most-discussed tickers on the popular Reddit forum WallStreetBets.